Search

Macroscopic hematuria is the visible presence of blood in the urine, and it can indicate the presence of urinary tract diseases such as infections, bladder cancer, benign prostatic hyperplasia, and urolithiasis. A study found that macroscopic hematuria is a powerful predictor of bladder and kidney neoplasia, with a probability of urological cancer of 10.3% in all patients. However, macroscopic hematuria is not very sensitive but highly specific for bladder and renal cancer. It is important to rule out other causes of macroscopic hematuria and properly evaluate patients with this symptom. [Extracted from the article]

The article focuses on the study of targeted molecular therapies such as bevacizumab, sunitinib and sorafenib as replacement for interferon-alpha in cases where metastatic clear cell renal cell carcinoma is treated with cytoreductive nephrectomy. Clinical data have reportedly shown the efficacy of targeted therapies. At the same time, studies on the role of cytoreductive nephrectomy and related questions about pre- or postsurgical systemic therapy are also noted.

This article pays tribute to Lee Hazlewood, a music producer, songwriter, and singer. Hazlewood has worked with musicians such as Duane Eddy, Phil Spector, Nancy Sinatra, Dean Martin, and Desi Arnaz. Hazlewood later went on to launch his own record label LHI, for Lee Hazlewood Industries. Article topics include Hazlewood's 2007 music album, "Cake or Death," his influence on the music industry, and his bout with kidney cancer. INSET: SERVING UP 'CAKE OR DEATH'.

The article present report to investigate rising cancer rates in military veterans.

The article discusses the occurrence and treatment of renal cell carcinoma (RCC). It references a study in the "Journal of Urology" which studied the symptoms of RCC. It presents several treatment options for RCC and their outcomes such as surgery, radiation therapy and chemotherapy. It offers drug treatments for RCC approved by the U.S. Food and Drug Administration (FDA) including bevacizumab, everolimus, and pazopanib.

This article reports that an independent data monitoring committee halted the phase-3 Renal Cell Cancer Treatment with Oral RAD001 Given Daily (RECORD1) trial of everolimus after the study met its primary endpoint of progression-free survival. The study was designed to determine the efficacy of the continuous mTOR inhibitor everolimus in patients with advanced renal cell carcinoma.

Relates the author's experiences with nurses during the hospice care of her father who had kidney cancer in London, England. Personality of nurses at the hospice facility; Efforts of nurses to relieve the pain of the patient; Nurse-patient relations.

The article discusses British farmer and terminal kidney cancer patient Jon Birchall's motorcycle trip on the roads of coastal Great Britain to raise funds for the James Whale Fund for Kidney Cancer. Topics covered include farming awards won by Birchall, the use of money raised to fund early-detection awareness campaigns, and the hiring of a research assistant to find ways to detect kidney cancer earlier and ultimately discover a cure.

The article discusses research which investigated the activation of transient receptor potential cation (TPRC) ion channels in kidney cancer cells by the molecule englerin, conducted by Mathias Christmann and colleagues, published in a 2015 issue of "Angewandte Chemie International Edition" journal. It explores the capacity of englerin to selectively kill kidney cancer cells, the overactivation of its Ca2+ ion channels, and the possible development of a cancer drug based on englerin.

The article reports on the discovery of a panel of scientists, which was formed as part of a settlement of a DuPont case in West Virginia in 2005, that exposure to perfluorooctanoic acid (PFOA) increases the risk of testicular and kidney cancers.

The article reports that researchers have finished the enantioselective total synthesis of (+)-englerin A, which uses the psychoactive ingredient catnip as a starting material. It mentions that Englerin A is a natural product obtained from a plant native to Tanzania that has a complex sesquiterpene structure and shows to have an activity against kidney cancer cell lines. It states that a team led by Mathias Christmann ascertained englerin A's absolute configuration through an entire synthesis.

The article presents information on a study which investigated the therapeutic use of sorafenib for advanced renal cell carcinoma.

The article reports that the National Comprehensive Cancer Network Guidelines Panel for Kidney Cancer in May 2009 has updated the clinical practice guidelines for the drug everolimus.

The article discusses a study on genes associated with lipid peroxidation that may increase the risk for kidney cancer. According to findings, variants of NOS2A, PTGS2 and GPX4 genes were associated with increased risk for kidney cancer, while ApoE1/C1 were associated with a decreased risk. Lee E. Moore, an epidemiologist and investigator at the National Cancer Institute, talks about the importance of these findings in terms of cancer prevention.

The article discusses research being done on the effectiveness of TroVax cancer vaccine. It references a study by Richard Harrop and colleagues, presented at the 20th European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AARC) Symposium in Geneva, Switzerland from October 21-24, 2008. Key findings indicate that the vaccine is capable of producing an immune response in several patients with bowel, kidney and prostate cancer.

The article discusses research which assessed type-1 and type-2 responses in T cells at baseline of patients with metastatic renal cell carcinoma. It references a study by researchers at the Lemer Research Institute, Taussing Cancer Institute and the Cleveland Clinic, published at a 2008 issue of "Clinical Cancer Research." The study has found that type-2 bias in the T cells of patients with metastatic renal cell carcinoma can be reversed following treatment with the tyrosine kinase inhibitor sunitinib.

The article focuses on a study which examined the safety and efficacy of sorafenib treatment among patients with renal cell carcinoma. Patients aged 70 or older and patients aged younger than 70 served as subjects in this study. Results showed that both younger and older patients treated with sorafenib have similar median progression-free survival (PFS). The study also found similar clinical benefit rates among young and old patients in the treatment group.

The article discusses research being done on the cost-effectiveness of sunitinib as a treatment for metatastatic renal cell carcinoma. It references a study published in the "Journal of Clinical Oncology" in 2008. The study suggested that sunitinib is more cost-effective than both interferon-alfa and interleukin-2 because patients assigned to the novel treatment lived longer, had longer progression-free health and had a better quality of life.

The article focuses on the ability of interferon-alpha plus bevacizumab combination in improving the progression-free survival and response rate in metastatic renal cell carcinoma compared with interferon-alpha alone, based on a study. The study randomly subjected the patients with previously untreated metastatic clear-cell renal cell carcinoma to interferon-alpha with or without bevacizumab. The results show that the combination treatment has better median time to progression.

The article reports on a case study which revealed that eating fatty fish such as salmon, herring, sardines and mackerel can significantly reduce the incidence of renal cell carcinoma in women. Around 61,433 woman in various age groups were included in the study. The study reported higher incidences of renal cell carcinoma among women who did not include significant of fatty fish in their diets.